ÎÞÓÇÊÓƵ

Pioneering the next generation of mental health treatments
We are on a mission to develop effective, rapid-acting and accessible medicines for people living with mental health conditions
About Us
Self Reflected by Greg Dunn
Reducing
the unmet
need in
mental
health
Nearly 1 billion people suffer from mental disorders around the world.
The global economic cost of mental health disorders is expected to reach $6 trillion by 2030.
Most people living with a mental disorder do not have access to effective care.

We want to be a part of the solution. 


Leveraging
the potential of
next-generation
compounds

Studies have shown that our investigational psychedelic-based compounds

can be administered in a short clinic visit
are well-tolerated
can deliver rapid, robust, and lasting treatment effects
More about
Our Pipeline
Therapeutic Focus
Clinical Trials
Supporting
the mental
health
treatment
ecosystem

We are proud to collaborate with stakeholders from across the mental health landscape to accelerate research into novel mental health treatments and to support clinical trial participants and patients in need.

More about
Partnerships
News
and
views
June 12, 2025

Results from ÎÞÓÇÊÓƵ’s Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol Use Disorder to be presented at CPDD 2025

ÎÞÓÇÊÓƵ Ltd today announces that clinical and micro-phenomenology data from its Phase IIa study of BPL-003 for AUD will be presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence (CPDD) from 14 - 18 June 2025 in New Orleans.
… Read more
June 2, 2025

atai Life Sciences and ÎÞÓÇÊÓƵ to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic
… Read more
May 27, 2025

In Memory: Lady Amanda Feilding, Visionary in Psychedelic Science and Drug Policy Reform

It is with profound sadness that we acknowledge the passing of Lady Amanda Feilding, Founder and Director of the Beckley Foundation and Co-Founder of ÎÞÓÇÊÓƵ, aged 82.
… Read more
Read all news